Therapeutic transformation for diabetic kidney disease

被引：8
|
作者：
Tuttle, Katherine R. [1 ,2 ,3 ]
Cherney, David Z. I. [4 ,5 ]
机构：
[1] Providence Hlth Care, Providence Med Res Ctr, Spokane, WA USA
[2] Univ Washington, Kidney Res Inst, Inst Translat Hlth Sci, Seattle, WA 98195 USA
[3] Univ Washington, Nephrol Div, Seattle, WA 98195 USA
[4] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Nephrol Div, Toronto, ON, Canada
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
基金：
美国国家卫生研究院; 加拿大健康研究院;
关键词：
D O I：
10.1016/j.kint.2020.10.003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Risks of kidney failure and heart failure are markedly reduced by inhibition of the sodium glucose cotransporter 2 (SGLT2) in patients with diabetic kidney disease. In a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial, drop-in SGLT2 inhibitor usage during the atrasentan enrichment period led to greater reduction in albuminuria compared with atrasentan alone. These data support the hypothesis of greater longer-term kidney protection by combination SGLT2 inhibition and endothelin A receptor antagonism that could be tested in future clinical trials. Copyright (C) 2020, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码：301 / 303
页数：3
相关论文
共 50 条
  • [1] Therapeutic Strategies for Diabetic Kidney Disease
    Matoba, Keiichiro
    [J]. DIABETOLOGY, 2021, 2 (01): : 31 - 35
  • [2] Therapeutic management of diabetic kidney disease
    Koya, Daisuke
    Araki, Shin-ichi
    Haneda, Masakazu
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2011, 2 (04) : 248 - 254
  • [3] Therapeutic Advances in Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Eleftheriadis, Theodoros
    Papachristou, Evangelos
    Liakopoulos, Vassilios
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [4] Complement, a Therapeutic Target in Diabetic Kidney Disease
    Budge, Kelly
    Dellepiane, Sergio
    Yu, Samuel Mon-Wei
    Cravedi, Paolo
    [J]. FRONTIERS IN MEDICINE, 2021, 7
  • [5] Therapeutic Potential of Astaxanthin in Diabetic Kidney Disease
    Naito, Yuji
    Uchiyama, Kazuhiko
    Handa, Osamu
    Aoi, Wataru
    [J]. CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 239 - 248
  • [6] Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
    Toth-Manikowski, Stephanie
    Atta, Mohamed G.
    [J]. JOURNAL OF DIABETES RESEARCH, 2015, 2015
  • [7] Emerging therapeutic options for managing diabetic kidney disease
    Walther, Carl P.
    Whaley-Connell, Adam
    Navaneethan, Sankar D.
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2017, 26 (05): : 335 - 337
  • [8] A New Therapeutic Era in the Management of Diabetic Kidney Disease
    Rosas, Sylvia E.
    Cherney, David Z. I.
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 280 - 281
  • [9] Potential New Therapeutic Agents for Diabetic Kidney Disease
    Turgut, Faruk
    Bolton, Warren Kline
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (05) : 928 - 940
  • [10] Targeting Macrophages: Therapeutic Approaches in Diabetic Kidney Disease
    Lin, Da-Wei
    Yang, Tsung-Ming
    Ho, Cheng
    Shih, Ya-Hsueh
    Lin, Chun-Liang
    Hsu, Yung-Chien
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (08)
12345